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lipids, the coordination of spatially separated lipid metabolic pathways, and lipid signaling mediated by soluble
proteins that may be localized some distance away from membranes. Alongside the well-established vesicular
transport of lipids, non-vesicular transport mediated by a group of proteins referred to as lipid-transfer proteins
(LTPs) is emerging as a key mechanism of lipid transport in a broad range of biological processes. More than a
hundred LTPs exist in humans and these can be divided into at least ten protein families. LTPs are widely distrib-
uted in tissues, organelles andmembrane contact sites (MCSs), as well as in the extracellular space. They all pos-
sess a soluble and globular domain that encapsulates a lipid monomer and they speciﬁcally bind and transport a
wide range of lipids. Here, we present themost recent discoveries in the functions and physiological roles of LTPs,
which have expanded the playground of lipids into the aqueous spaces of cells.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Signaling lipid
Biological membranes
Non-vesicular lipid trafﬁcking
Metabolism
Transport
Lipid-transfer proteins
Lipid-binding domains
Membrane contact sites
Organelles
Systems biology
Biomolecular networksContents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2. Lipids and membranes of eukaryotic cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.1. Lipid diversity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.2. Lipid compartmentalization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3. Lipid-transfer proteins: variations on a common theme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.1. Lipid recognition by lipid-transfer proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
3.2. Molecular architecture of lipid-transfer proteins deﬁning their localization and function . . . . . . . . . . . . . . . . . . . . . . . . . 32
4. Compartmentalized functions of lipid-transfer proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4.1. Lipid-transfer proteins transfer lipids between cellular membranes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
4.2. Lipid-transfer proteins can act as chaperones and present lipids to other proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36holesteryl ester transfer protein; ER, endoplasmic reticulum; FABP, fatty acid-bindingprotein; FFAT, diphenylalanine in an acidic
leotide exchange factor; GLs, glycerolipids; GLTP, glycolipid transfer protein; GLTPD1, glycolipid transfer protein domain-
rotein; GPL, glycerophospholipids; LTD, lipid-transfer domain; LTP, lipid transfer protein; MCS, membrane contact site; ML,
sequence; NPC, Niemann–Pick C; OSBP, oxysterol-binding protein; OSBPL1A, oxysterol-binding protein-related protein 1;
KHA8, pleckstrin homology domain-containing family A member 8; PPARD, peroxisome proliferator-activated receptor δ; PH,
tidylinositol; PIP, phosphatidylinositol phosphate; PITP, PI-transfer protein; PITPNM1,membrane-associated PITP 1; PM, plasma
eptorα; SL, sphingolipids; SCP2, sterol carrier protein 2; StAR, steroidogenic acute regulatory protein; START, StAR-related lipid-
otein; VAPA, vesicle-associated membrane protein-associated protein A.
Laboratory (EMBL), Molecular Medicine Partnership Unit (MMPU), Meyerhofstrasse 1, D-69117 Heidelberg, Germany.
ter (DCRC), Cell Death and Metabolism, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
oint Research Centre for Computational Biomedicine (JRC-COMBINE), Aachen, Germany.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
31A. Chiapparino et al. / Progress in Lipid Research 61 (2016) 30–394.3. Lipid-transfer proteins as lipid sensors, linking lipid metabolism to signaling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.4. Lipid-transfer proteins often work together and are organized in functional, cellular networks . . . . . . . . . . . . . . . . . . . . . . 37
5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Conﬂicts of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371. Introduction
The tight control of lipid biosynthesis and degradation in time and
space largely accounts for the ﬁne-tuned and differentiated lipid com-
position of eukaryotic membranes. Pathways of lipid metabolism need
to be coupled to a variety of lipid transport systems as enzymes catalyz-
ing sequential steps of a reaction often localize tomembranes of distinct
organelles.Moreover, lipids often exert their biological activity – as both
structural elements and signaling molecules – at places distant from
their site of synthesis [1]. The spontaneous dissociation of lipids from
membrane bilayers into and through the aqueous space occurs very
slowly and rapid, directed and regulated transport is achieved via vesic-
ular and non-vesicular mechanisms. Over the past decades, lipid-
transfer proteins (LTPs) have emerged as an important mechanism of
non-vesicular lipid transport. They were initially identiﬁed in the 80th
from various sources of animal and plant tissues, as cytosolic factors
able to transfer lipids in vitro [2–5]. Their soluble, globular lipid-
transfer domain (LTD) encapsulates interacting lipids (Fig. 1) and
carries them through the aqueous space within cellular, tissue and
whole body compartments. LTPs are widely distributed across cellular
compartments and tissues. Accumulating evidence suggests that struc-
tural features of LTPs ensure the directionality of the transfer froma spe-
ciﬁc donor membrane to a speciﬁc acceptor membrane or protein,
therebyplacing LTPs at the interface between signaling andmetabolism.
This review highlights the state-of-the-art knowledge regarding the
role of LTPs in the control of whole-body homeostasis. We provide an
integrated map showing how these activities are compartmentalized
and which metabolite(s) they involve. Finally, we zoom in on some of
their structures and functions and critically discuss the impact of their
activity on human health and disease.STARTLipocalin ML
PITP SCP2 NPC1 N
Fig. 1.Cartoon displays of the three-dimensional structures of ligand-bound LTDs. The LTDs disp
2IFB); the ML domain of the bovine NPC2 in complex with cholesterol sulfate (PDB entry code
code 2E3O); the LBP/BPI/CETP domain of the CETP in complexwith twomolecules each of chole
Osh4 in complexwith ergosterol (PDB entry code 1ZHZ); the PITP domain of the rat PITP in com
like 3 in complex with palmitate (PDB entry code 3BKR); the NPC1 NTD of the NPC1 in comple
withα-tocopherol (PDB entry code 1R5L); and the GLTP domain of the GLTP in complex with l
yellow, respectively. The bound ligands are shown as sticks with the carbon, nitrogen, oxygen,2. Lipids and membranes of eukaryotic cells
2.1. Lipid diversity
Lipids are one of themost abundant classes of cellularmetabolites [6]
and are important for energy supply and storage, the construction of cel-
lular membranes, trafﬁcking, and signaling. The complete repertoire of
lipids in eukaryotes comprisesmore than 1000 different specieswith di-
verse structures and functions [7]. About 5% of eukaryotic coding genes
encode proteins involved in the metabolism and transport of lipids [8].
Lipid species are classiﬁed into seven categories according to their
chemical structures and their pathways of biosynthesis: fatty acyls,
glycerolipids (GLs), glycerophospholipids (GPLs), sphingolipids (SLs),
sterol lipids, prenol lipids, and saccharolipids (see LIPID MAPS, http://
www.lipidmaps.org/data/classiﬁcation/LM_classiﬁcation_exp.php).
The GLs (such as diacylglycerol and triacylglycerol) and GPLs are the
products of fatty acids esteriﬁed on glycerol. GPLs alone represent
∼75 mol% of total cellular lipids (reviewed in [9]) and their chemical
structures, most commonly comprising two esteriﬁed fatty acids, make
them key elements for the assembly of lipid bilayers. The types of head
groups conjugated to the third glycerol hydroxyl group further catego-
rize GPLs into classes that include phosphatidylcholine (PC), phosphati-
dylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine
(PS), and phosphatidic acid (PA). The phosphorylation of PI at the 3-,
4-, and 5-hydroxyl groups of the head group inositol ring gives rise to
the series of phosphatidylinositol phosphates (PIPs), well known for
their signaling function [10]. The GPLs are further subdivided into differ-
ent species based on structural variations in the numbers of carbons and
in the numbers and positions of unsaturations of the esteriﬁed fatty
acids.CRAL-TRIO GLTP
LBP/BPI/CETP OSBP
TD
layed are: the lipocalin domain of the rat FABP2 in complexwith palmitate (PDBentry code
2HKA, chain B); the START domain of the CERT in complex with C16-ceramide (PDB entry
steryl ester andphosphatidylcholine (PDB entry code 2OBD); theOSBPdomain of the yeast
plexwith PC (PDB entry code 1 T27); the SCP2 domain of the yellow fever mosquito SCP2-
x with cholesterol (PDB entry code 3GKI); the CRAL-TRIO domain of the TTPA in complex
actosylceramide (PDB entry code 1SX6). The helices and β-strands are colored salmon and
and phosphate atoms colored green, blue, red, and orange, respectively (Figs. 2–4).
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a common four-ring structure and comprise 12–14mol% of the total cel-
lular lipids (reviewed in [11]). SLs account for 8–12mol% of total cellular
lipids [9,11] and they share a sphingoid base backbone that can be con-
jugated to a fatty acid via an amide bond and to a variety of head groups
including one or multiple sugar residues. Vitamin A and E belong to the
category of prenol lipids. Vitamin A (retinol) and its derivatives (reti-
noids) have three structural determinants: a polar terminus, a conjugat-
ed side chain and a β-ionone ring. Retinol is the precursor for the
synthesis of two important metabolites, retinal and retinoic acid,
which have a role in vision [12] and gene expression [13], respectively.
Vitamin E is a major fat-soluble antioxidant [14] and its most abundant
form in mammals is α-tocopherol. It has a structure that comprises a
chromanol ring, with four methyl groups and a phytyl side chain, and
three chiral centres in the RRR conﬁguration (reviewed in [15]).
2.2. Lipid compartmentalization
Cellular lipids are primarily assembled intomembrane lipid bilayers,
in which they form dynamic networks of interactions with each other
and with proteins associated with the periphery or integrated into the
membrane. A number of observations indicate that lipids are highly or-
ganized within the eukaryotic cell. Firstly, different lipid species are not
evenly distributed among the various cellularmembranes. For example,
signaling lipids such as PS, PI(4,5)P2, and PI(3,4,5)P3 are predominantly
found in the plasmamembrane (PM), whereas PI(3,5)P2 localizes to the
endosomalmembranes [7]. PIPsmediate and spatiotemporally organize
both acute and constitutive signals through the recruitment of cytosolic
proteins, such as protein kinases, to speciﬁc membranes. The uneven
distribution of lipids also dictates the physical nature of eukaryotic
membranes. For example, compared with those of the endoplasmic re-
ticulum (ER) and Golgi apparatus, GPLs of the PM are composed of lon-
ger andmore saturated fatty acids thatmake the PMgenerally thick and
rigid (reviewed in [9]). Secondly, cellular membranes are laterally het-
erogeneous as lipids cluster and partition into lateral domains as a result
of lipid–lipid interactions. For example, the PM forms sphingolipid- and
sterol-rich lateral domains referred to as lipid rafts [16,17]. Finally, cel-
lular lipids are distributed differently between the two leaﬂets of a
lipid bilayer. Enzymes involved in lipid biosynthesis often perform
these reactions in only one of the two leaﬂets. For instance, PIPs are syn-
thesized at the cytosolic leaﬂets of membranes because soluble PI ki-
nases are recruited to the membrane periphery from the cytosol. PS is
synthesized in the ER, but is highly enriched at the cytosolic leaﬂet of
the PM due to speciﬁc non-vesicular transport through the cytosol
[18–20]. The exposure of PS at the cell surface acts as a signal for apopto-
sis [21].
3. Lipid-transfer proteins: variations on a common theme
3.1. Lipid recognition by lipid-transfer proteins
Within the human genome there are about 125 distinct genes that
together encode at least ten families of LTPs. They are generally
expressed in virtually all tissues in human (Fig. 2; Supplementary
Table S1), but some families of LTPs, such as the lipocalins, show prefer-
ences for some cell types (e.g. the skin and soft tissues). Each family is
deﬁned by the distinct structural fold of their globular, water-soluble
LTD (Fig. 1). For example, the MD-2-related lipid-recognition (ML) do-
mains [22,23] and the lipocalin domains [24,25] mainly comprise β-
strands that completely surround the binding cavity (Fig. 1). The bind-
ing pockets of the oxysterol-binding protein (OSBP), LBP/BPI/CETP,
CRAL-TRIO, StAR-related lipid-transfer (START), sterol carrier protein
2 (SCP2), Niemann–Pick C1 (NPC1) N-terminal, and PI transfer protein
(PITP) domains are deﬁned by both β-strands and α-helices [26–32]
(Fig. 1). By contrast, the secondary structure of the glycolipid transfer
protein (GLTP) domain solely consists of helices [33] (Fig. 1).Despite their apparent structural diversity, all LTDs exhibit striking
similarities in theirmode of lipid interactions. All have a polar outer sur-
face and a deep hydrophobic or amphiphilic cavity shaped as a tunnel.
Lipid molecules are accommodated inside this cavity and are shielded
from the surrounding aqueous environment. Structures are available
for the ten known LTD families and these represent snap-shots of the
protein–lipid interactions that take place during physiological lipid
transport (Fig. 1). These structures commonly show the LTD cavity
enclosing the majority of the bound lipid and providing hydrophobic
contacts to non-polar groups of the molecule. Once the lipid ligand is
bound, a ﬂexible motif referred to as a “lid” or a “cap” often blocks the
cavity entrance, and sterically disables its dissociation. These “lids”
sometimes consist of a single loop that, in the case of PITP, can swing
open upon PC binding [32,34]. In the lipocalin domain, the lid forms a
so-called helix–loop–helix motif (Fig. 1). Most LTD–lipid complexes
are stoichiometric, involving a single lipid molecule, but there are a
few interesting exceptions that show that some LTD can simultaneously
bind tomore than one ligand. For example, the LBP/BPI/CETP domain of
the cholesteryl ester transfer protein (CETP) carries twomolecules each
of cholesteryl esters and PC, and the lipocalin domain of fatty acid-
binding protein 1 (FABP1) binds two molecules of oleic acid [25].
The current knowledge of LTP–lipid interactions has already shed
light on the interplay between LTPs and lipids from all categories
(Fig. 3; Supplementary Table S2). Despite the fact that they share similar
folds, members of the same LTD family show a surprisingly broad lipid-
binding speciﬁcity (Fig. 3; Supplementary Table S2). For instance, theML
domain protein lymphocyte antigen 96 (LY96) binds bacterial lipopoly-
saccharide [35], whereas another ML domain protein, NPC2, binds cho-
lesterol [36]. Similarly the lipocalin domain proteins have binding
speciﬁcity for a variety of lipids and lipophilic molecules including reti-
noids, steroids and fatty acids (Fig. 3; Supplementary Table S2). The
ligand-binding speciﬁcity is created by a series of polar groups on the li-
gands such as the head groups of GPLs and SLs that are often engaged in
intermolecular hydrogen bonding to LTD residues at the interior of the
cavity (e.g. the ceramide-transfer protein (CERT) START domain–
ceramide complex [29]) or at the outer surface (e.g. the GLTP–
lactosylceramide complex [33]). In addition, the volume and shape of
the lipid-binding cavity also inﬂuence the LTD–lipid interactions and
can sterically restrict the size of ligands. For example, the CERT START
domain can bind different ceramide species, but not those with long
amide-acyl chains that are too bulky for its small hydrophobic pocket
[29]. For those LTPs in a spatially restricted compartment, LTP–lipid in-
teractions are also inﬂuenced by the accessibility and availability of
lipids. These LTPs can associate with non-physiological lipids when
brought into an unnatural environment, for example upon heterologous
expression [18,31,37]. The characterization of LTP–lipid interactions are
thus a demanding and on-going task and, for the majority of LTPs, the
identity of their cargoes remains elusive (Fig. 3, Supplementary
Table S2).
3.2. Molecular architecture of lipid-transfer proteins deﬁning their
localization and function
LTPs frequently also harbor domains ormotifs that specify their sub-
cellular location (Figs. 3 and 4; Supplementary Table S3) or mediate in-
teractions with downstream protein effectors, such as enzymes,
transmembrane transporters, other LTPs or nuclear receptors (see
below).
The function of many LTPs requires their precise targeting to speciﬁc
organellar membranes through the recognition of membrane (or lipid)
signatures. Membrane targeting sometimes involves transmembrane
helices (for example in NPC1 [38]) or the lid of the LTDs. A good exam-
ple is the ML domain of the ganglioside GM2 activator protein (GM2A),
the lid of which interacts with the inner lysosomal membranes through
two loops present at the entrance of the lipid-binding cavity [39] to fa-
cilitate the loading of its cargo (the GM2 ganglioside) [23]. However,
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Fig. 2. Expression pattern of LTPs in human tissues. LTPs are generally expressed in virtually all tissues in human. Some of LTPs are pleiotropic across almost all the tissues, while others
show a more speciﬁc occurrence. This pattern suggests that the expression of LTPs is closely related to the functions performed by different cell types. The heat map shows that, overall,
each tissue expressed between 6 and 29 LTPs. LTP families and tissueswith similar functions tend to cluster together e.g. gastrointestinal glandular cells, or lymphoid tissues. The datawas
extracted from the expert curated immunohistochemistry and RNA-seq dataset of the Human Protein Atlas (HPA; version 13) [108]. The LTPs are color coded according to their LTD fam-
ilies. The tissues are colored by functional and histological similarities. A total of 45 LTPs in 82 tissues have at least one high conﬁdence expression value. According to the HPA, high con-
ﬁdence is determined based on a number of criteria considering the congruence of immunohistochemistry of multiple antibodies and RNA level evidences. HPA scores the level of
expression as high, medium, low or not detected, based on evaluation of immunohistochemistry staining and RNA levels (FPKM values). Colored ﬁelds show the 3 levels of expression
(protein abundance), and white ﬁelds the cases where the protein is considered to not be expressed, as it has been measured, but not detected. Fields marked with dots signify those
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(lack of multiple good quality antibodies and/or supportive RNA level expression data). They were thus omitted. Both LTPs and tissues are clustered with unsupervised hierarchical
clustering.
33A. Chiapparino et al. / Progress in Lipid Research 61 (2016) 30–39targeting often requires the presence of specialized domains, such as the
pleckstrin homology (PH) or the Golgi dynamic (GOLD) domains that
bind lipids and/or other proteins. Remarkably, PH domains – well
known for their PIP-binding activity – are present in several families
of LTPs: the OSBP, the START, the GLTP and the CRAL-TRIO domain fam-
ilies (Fig. 4). However, these PH domains are sometimes difﬁcult to
identify on the basis of sequence analyses alone. For example, the cryp-
tic PH domain of neuroﬁbromin (NF1, which belongs to the CRAL-TRIO
domain family)was overlooked by the classical algorithm, and its detec-
tion required biochemical and structural analyses [37].
The precise, spatiotemporally regulated targeting of LTPs to speciﬁc
subcellular membranes often requires the integration of multiple low-
afﬁnity interactions. This is well known for CERT and OSBP, the localiza-
tion of which at MCSs between the Golgi and the ER requires thepresence of both a PH domain and a diphenylalanine in an acidic tract
(FFAT) motif [40,41]. In the case of OSBP, its PH domain simultaneously
interactswith the trans-Golgi network (TGN) resident ADP-ribosylation
factor 1 (ARF1) and PI(4)P [42], whereas its FFAT motif interacts with
the ER transmembrane protein, vesicle-associated membrane protein-
associated protein A (VAPA) [43–46]. LTPs also possess a signal peptide
and are sorted to various subcellular compartments or are secreted
(Fig. 3; Supplementary Table S3). Some possess a nuclear localization
sequence (NLS). Interesting examples are the lipocalin domain proteins
cellular retinoic acid-binding protein 2 (CRABP2), FABP4, and FABP5.
The binding of these proteins to their lipid ligands induces intramolec-
ular rearrangements that lead to the exposure of an otherwise hidden
NLS and the targeting to acceptor proteins localized in the nucleus (de-
scribed in more detail below).
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Fig. 3. Subcellular localizations and lipid-binding speciﬁcities of human lipid-transfer proteins. Themembers of the ten families of LTPs are displayed. The systematicmanual annotation of
their localization shows that these proteins are localized in virtually every compartment within the cell and, in some cases, they can be secreted. Moreover, within families they do not
necessarily share the same binding speciﬁcity, while across families it is possible to ﬁnd afﬁnity for the same lipid. Colors are speciﬁc for each LTD family as indicated in the legend.
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interaction, or catalytic domains that illustrate the broad functional di-
versity of LTPs (Fig. 4). Remarkable examples are members of the
CRAL-TRIO and START domain families that frequently harbor signaling
domains such as protein kinase (TRIO, KALRN), protein phosphatase
(PTPN9), Src homology 3 (SH3)(KALRN, MCF2L, TRIO), RhoGAP
(ARHGAP1, ARHGAP8, DLC1, STARD8, STARD13), RhoGEF (KALRN,
MCF2, MCF2L, MCF2L2, TRIO) and RasGAP (NF1) domains, or metabolic
domains such as themacro domain – a bindingmodule for poly(ADP-ri-
bose), ametabolite of NAD+ (GDAP2) – and the 4-hydroxybenzoyl-CoA
thioesterase domain (HotDog)(ACOT11, ACOT12).
4. Compartmentalized functions of lipid-transfer proteins
4.1. Lipid-transfer proteins transfer lipids between cellular membranes
One of the ﬁrst proposed functions of LTPs was the non-vesicular
transfer of lipids between biological membranes (Fig. 5). This activitywas initially described some 30 years ago in in vitro reconstituted
biochemical systems [47–49]. More recently, mechanisms of non-
vesicular lipid transfer between membranes have also been demon-
strated in vivo [18,50], in which the LTPs have important functions
such as spatially organizing lipids and connecting lipid metabolic
pathways that are distributed across distant organelle membranes [40,
41,51,52]. LTPs have also been proposed to contribute to the still-
elusive membrane-tethering mechanisms that drive the formation of
MCSs [53,54]. In particular, they link the ER – the major site of lipid
synthesis – to several other organelles such as the Golgi [41], the mito-
chondria [55,56] and the PM [18].
The ER and Golgi apparatus are populated by many LTPs such as
OSBP, oxysterol-binding protein-related protein 9 (OSBPL9), glycolipid
transfer protein domain-containing protein 1 (GLTPD1), pleckstrin
homology domain-containing family A member 8 (PLEKHA8), the
membrane-associated PITP 1 (PITPNM1) and CERT, and their lipid-
transfer activities contribute to sterol lipid, GPL and SL homeostasis
along the different compartments of the secretory pathways (ER/cis-
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35A. Chiapparino et al. / Progress in Lipid Research 61 (2016) 30–39Golgi and TGN/PM) [57]. For example, CERT transfers ceramide from the
ER to the Golgi where it generates a pool of ceramide that acts as a pre-
cursor for the synthesis of sphingomyelin that is required at the PM [40].
In other cases, the lipid-transfer activity of LTPs contributes to the accu-
mulation of lipids in different organelles and the building of lipid gradi-
ents such as the one observed along the secretory pathway. For
instance, OSBP transfers cholesterol from the ER to the TGN against
the concentration gradient of cholesterol, which increases along the se-
cretory pathway, i.e. from the ER to the PM (the PM comprises 60% of
the total cellular cholesterol [58,59]). The OSBP-mediated transfer of
cholesterol is coupled to the OSBP-mediated reverse-transfer of PI(4)P
from the TGN to the ER, where PI(4)P is dephosphorylated (to PI) by
the phosphatidylinositide phosphatase SAC1. PI in the ER, in its turn,
is transferred – via another LTP, PITPNM1 – to the Golgi apparatus[41,57,60] where it is phosphorylated by a PI 4-kinase [60]. According
to this model, cycles of PI(4)P dephosphorylation (in the ER), PI trans-
port and PI phosphorylation (in the TGN) provide the energy required
for the OSBP-dependent cholesterol transfer and the accumulation of
sterol along the secretory pathway. This mechanism is also conserved
in Saccharomyces cerevisiae, in which the oxysterol-binding protein ho-
molog 4 (Osh4)/Kes1 and a CRAL-TRIO domain protein, Sec14, act to-
gether to guarantee the net PC–sterol exchange sustained by the ATP
hydrolysis catalyzed by the Golgi PI-kinase PIK1 [54].
Some LTPs also transport hydrophobic vitamins. For instance, the
CRAL-TRIO domain protein α-tocopherol (a form of vitamin E) transfer
protein (TTPA) is part of the machinery involved in the secretion of
vitamin E from hepatocytes. TTPA mutations in humans cause ataxia
with vitamin E deﬁciency (AVED) [61,62]. In hepatocytes, TTPA extracts
TRANSPORTERS
Saturated
Unsaturated
Cholesterol
STAR
RBP4
NPC2
Transferred lipid
Enzyme LTP
Transcription factorTM transporter
CHAPERONES
Lipid homeostasis
Signaling
Structural organization of membranes
FABP4
CRABP2
a b c SENSORS
RhoGEF
RhoGAP
RasGAP
4HBT
Kinase
Phosphatase
Signaling
LTP
LTP
LTP
Signaling domains
GM2A
RBP1
FABP5
CERT
OSBP
PITPNM1
Fig. 5. Lipid-transfer proteins havemultiplemodes of action. a, LTPs can transfer lipids between cellularmembranes and act as transporters. b, Some LTPs (chaperones) present lipids to an
acceptor protein (e.g. enzymes, LTPs, transmembrane (TM) transporters or transcription factors). c, The LTD can be engaged in intramolecular interactionswith other domains (illustrated
here in purple) or proteins (not illustrated). Binding to the lipid cargo acts as a trigger that induces conformational changes and leads to the activation of signaling. This mechanism is
sometimes coupled to themechanisms described in a and b. LTPs have pleiotropic functions and canmodulate lipid homeostasis, signaling and the structural organization of membranes.
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[63–65]. This implies speciﬁc interactions between the TTPA/vitamin E
complex and the head group of a PM-localized PIP2 – PI(3,4)P2 or
PI(4,5)P2 – leading to the exchange of vitamin E for the PIP2. The fate of
the extracted, TTPA-bound PIP2 is not yet clear. The recycling of TTPA –
and the directionality of the vitamin E transfer –might imply the release
of PIP2 to an as yet unknown acceptor membrane or its channeling to
metabolic enzymes such as a lipid kinase or phosphatase (the role of
LTPs in the presentation of lipids to another protein is discussed in the
next section).
LTPs also have important lipid-transfer functions in the extracellular
milieu and in the bloodstream. Many LTPs are indeed secreted (Fig. 3,
Supplementary Table S3). For example, the phospholipid transfer pro-
tein (PLTP) and CETP transfer GPLs and cholesteryl ester/triacylglycerol,
respectively, between various lipoprotein particles,which are organized
assemblies of proteins and lipids thatmove cholesteryl esters and triac-
ylglycerol in the plasma. These LTPs modulate the size, lipid composi-
tion, identity and function of the lipoprotein particles [66].
4.2. Lipid-transfer proteins can act as chaperones and present lipids to
other proteins
An interesting feature shared by some LTPs is their ability to transfer
their lipid cargoes to acceptor proteins such as enzymes, transmem-
brane transporters, nuclear receptors, transcription factors or other
LTPs (Fig. 5). They act as chaperones, presenting speciﬁc lipids to spe-
cialized downstream protein effectors. The dysfunction of these impor-
tant pathways in humans frequently leads to disease, some examples of
which are given below.
A number of LTPs can transfer lipids to downstream enzymes
(Fig. 5). For example, GM2A is a lysosomal LTP that works as a speciﬁc,
essential cofactor for the lysosomal glycosphingolipid-degrading en-
zyme, β-hexosaminidase A [67]. GM2A extricates GM2 gangliosides
out of the inner lysosomal membranes and makes them accessible for
the soluble β-hexosaminidase A [68–71]. A recessively inherited deﬁ-
ciency in GM2A leads to the AB variant of GM2-gangliosidosis, a disor-
der characterized by the neuronal accumulation of GM2 [72–74].Another example, is the lipocalin domain protein, retinol-binding pro-
tein 1 (RBP1), that transfers retinol (vitamin A) from its trans-plasma
membrane transporter (stimulated by retinoic acid 6, STRA6) to intra-
cellular retinol-metabolizing enzymes such as the lecithin retinol acyl-
transferase (LRAT) [75] or the retinol dehydrogenase 16 (RDH16) [76–
78].
Some LTPs transfer lipids to small molecule transporters or to other
LTPs (Fig. 5). This represents the mode of action of the START domain
protein steroidogenic acute regulatory protein (StAR), which transfers
cholesterol from the cholesterol-rich outer mitochondrial membrane
to the translocator protein (TSPO) [79–81]. TSPO further transfers cho-
lesterol to the cholesterol-poor inner mitochondrial membrane, where
cholesterol is a precursor for steroidogenesis [82]. Loss-of-function mu-
tations in StAR lead to lipoid congenital adrenal hyperplasia [83–85], a
potentially lethal disease arising fromdefects in the early stages of adre-
nal cortisol synthesis.
LTPs can also translocate from the cytoplasm to the nucleus and
present their lipid cargoes to nuclear receptors, a class of transcription
factors (Fig. 5). Two good examples are the epidermal FABP5 and
CRABP2, which translocate to the nucleus upon binding to retinoic
acid and tunnel it to the peroxisome proliferator-activated receptor δ
(PPARD) and the retinoic acid receptor-activated receptorα (RARΑ), re-
spectively [86–89]. The two nuclear receptors activate opposing signal-
ing cascades: RARΑ activates a pro-apoptotic cascade, whereas PPARD
promotes cell survival [90–92], cell proliferation and tumorigenesis
[93]. The ratio between FABP5 and CRABP2 thus determines pro- and
anti-apoptotic responses. Similarly, the adipocyte FABP4 binds a variety
of ligands, including linoleic acid and trogliatazone – a drug developed
to treat type 2 diabetes – and present them to another nuclear receptor,
the peroxisome proliferator-activated receptor γ (PPARG) [89].
4.3. Lipid-transfer proteins as lipid sensors, linking lipid metabolism
to signaling
LTPs can also act as lipid sensors that undergo conformational
changes following the binding of speciﬁc lipids. These structural chang-
es regulate downstream biological processes such as signaling cascades,
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acts as molecular probes that sense ﬂuctuations in the levels of speciﬁc
lipids in their environment and elicit the appropriate cellular adapta-
tion. In many cases, the sensing mechanisms are tightly coupled to the
lipid-transfer activity of the LTPs.
Some LTPs act asmolecular scaffolds. A good example is OSBP,which
exchanges cholesterol and PI(4)P between the ER and the TGN but also
has a signaling function [41]. When the levels of cholesterol are high,
OSBP – loadedwith cholesterol – acts as a scaffold for both a serine/thre-
onine (PP2A) and a tyrosine (PTPBBS family) phosphatase [94,95]. The
resulting hetero-oligomer dephosphorylates pERK, and thus down reg-
ulates the MAP kinase signaling cascade. A decrease in the cellular cho-
lesterol level induces cholesterol dissociation and conformational
changes in OSBP that promote the disassembly of the heteroligomer
[95]. In the case of the oxysterol-binding protein-related protein 1
(OSBPL1A), binding to cholesterol induces conformational changes
that expose an otherwise hidden ankyrin repeat. OSBPL1A bound to
cholesterol acts as a scaffold for both the small GTPase Ras-related pro-
tein RAB7A (through OSBPL1A's ankyrin repeat), the membrane lipid
bilayer of late endosomes (LE) [96,97] (through OSBPL1A's PH domain)
and the RAB7A-interacting lysosomal protein (RILP) (through RAB7A).
The trimeric complex OSBPL1A–RAB7A–RILP recruits the p150Glued sub-
unit of the dynein–dynactinmotor and drives the LE to theminus end of
themicrotubules [98]. Conversely, upon cholesterol depletion, OSBPL1A
is in its cholesterol-free conformation in which the ankyrin repeat is
hidden but a FFAT motif is exposed. The FFAT motif interacts with the
ER-resident protein VAPA [44,45], favoring the formation of LE-ER con-
tacts and preventing the binding of the p150Glued subunit [97].
Many LTPs carry domains with enzymatic activities such as protein
kinase, protein phosphatase, thioesterase, guanine nucleotide exchange
factor (GEF) and GTPase-activating protein (GAP) [83] (see above) do-
mains, which suggests the existence of mechanisms of intra-molecular
regulation. In these cases, the co-occurrence of multiple domains in a
single protein may contribute to rapid spatiotemporal regulation of sig-
naling. In many cases, however, the exact mechanisms remain elusive.
For example, ARHGAP1 belongs to the CRAL-TRIO domain family and
also contains a RhoGAP domain [99]. This domain interacts with the
prenyl group of the target GTPase (probably Rab5 and/or Rab11 local-
ized on the endosome and on endocytic recycling compartments, re-
spectively) and releases an auto-inhibitory intra-molecular interaction
between the C-terminal RhoGAP domain and the CRAL-TRIO domain
[100].
4.4. Lipid-transfer proteins often work together and are organized in
functional, cellular networks
Some LTPs act in more complex networks. For example, NPC1 and
NPC2 [101] are two lysosomal LTPs, mutations in which lead to the
Niemann–Pick disease type C, an inherited, neurodegenerative disorder
[102,103]. NPC2 is a soluble LTP that extracts cholesterol from the inner
lysosomal membranes and transfers it to the N-terminal domain of
NPC1, a transmembrane LTP located at the lysosomal delimiting mem-
brane. This process – called “hydrophobic handoff” – is crucial for the
export of cholesterol from the lysosomal compartment [104], but the
molecular mechanism of cholesterol export after its delivery to the
NPC1 N-terminal domain remains elusive. Another LTP, the oxysterol-
binding protein-related protein 5 (OSBPL5), may contribute to the for-
mation of LE–ER MCSs, bind the cholesterol delivered by NPC1 and
transfer it to the ER [13].
Other interesting examples, are RBP1 and RBP4, two LTPs belonging
to the lipocalin domain family. Both act in the same pathway involved
in retinol homeostasis and signalling. RBP4 is a secreted LTP that binds
and transfer retinol from the liver to extra hepatic organs [105], which
are highly dependent on retinol for their function [106,107]. There,
RBP4 transfers its cargo to the STRA6 transmembrane receptor. Retinol
uptake by STRA6 triggers the Janus kinase 2 (JAK2) and signaltransducer and activator of transcription 5 (STAT5) mediated
signalling. Simultaneously, the intracellular the RBP1 binds the retinol
taken up by STRA6 and transfers it to enzymes responsible for the
conversion into esters – the storage form of many lipids – or into all-
trans RA – important in regulating cellular proliferation, differentiation,
and apoptosis (see above) [75].
5. Conclusion
The number of physiological roles reported for LTPs has greatly in-
creased in the past decades. The current, yet incomplete, overview of
the protein–lipid interaction networks of LTPs already includes all
lipid categories and covers essentially all subcellular localizations as
well as extracellular spaces. Such an overview has challenged our idea
of themembranes of eukaryotic cells as a set of islands that isolate lipids,
and has illuminated the movement of lipids along complex and inter-
connected networks of “highways” specialized in selective and direc-
tional transport. Lipid metabolic pathways that require LTPs for their
proper functioning are no longer the exception, and it is now becoming
apparent that LTPs constitute integrated parts of lipid metabolic net-
works. Further investigations into the physiological activities of LTPs
will thus increase our understanding of the mechanisms of these meta-
bolic networks and how they are regulated in health and disease.
Efforts in both biochemistry and structural biology have elucidated
the lipid-binding mechanisms of many LTPs. Nevertheless, novel
protein–lipid interactions are still being uncovered, even for members
of well-studied LTP families, indicating that our understanding of the
mechanisms of action of LTPs is incomplete. The fact that the lipid-
binding speciﬁcity of LTPs is difﬁcult to predict highlights the need for
systematic and unbiased monitoring of the protein–lipid interactions
of LTPs. Moreover, even though humans possess over one hundred
LTP genes, this number is very small compared to that of the human
lipid repertoire. Novel LTPs evolutionally unrelated to previously
known LTPs continue to be reported, and the actual number of LTPs
and LTP-interacting lipids in humans is likely to expand in the future.
The physiological roles of most human LTPs remain poorly assigned.
Among the numerous compartmentalized LTP networks visualized in
the integrated maps we provide here, physiological roles have been
demonstrated for only a small subset. The complex series of transient in-
teractionswith cargoes, donors, acceptors, and/or downstreameffectors
together deﬁne the physiological role of an LTP, and mapping these re-
quires extensive experimental efforts. This complexity is further in-
creased by the fact that most LTPs are multi-domain proteins, in which
each constituting domain can have different, inter-dependent functions.
Despite these challenges, recent advances in -omics and network
analyseswill no doubt support the effort in elucidating thephysiological
roles of LTPs and shed further light on their modes of action in health
and disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.plipres.2015.10.004.
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